- Home
- PLAY vs NTLA Comparison
PLAY vs NTLA Comparison
Compare PLAY & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLAY
- NTLA
- Stock Information
- Founded
- PLAY 1982
- NTLA 2014
- Country
- PLAY United States
- NTLA United States
- Employees
- PLAY N/A
- NTLA N/A
- Industry
- PLAY Restaurants
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PLAY Consumer Discretionary
- NTLA Health Care
- Exchange
- PLAY Nasdaq
- NTLA Nasdaq
- Market Cap
- PLAY 1.5B
- NTLA 1.4B
- IPO Year
- PLAY 1995
- NTLA 2016
- Fundamental
- Price
- PLAY $28.41
- NTLA $12.90
- Analyst Decision
- PLAY Buy
- NTLA Buy
- Analyst Count
- PLAY 9
- NTLA 17
- Target Price
- PLAY $57.50
- NTLA $56.63
- AVG Volume (30 Days)
- PLAY 2.4M
- NTLA 2.5M
- Earning Date
- PLAY 12-10-2024
- NTLA 11-07-2024
- Dividend Yield
- PLAY N/A
- NTLA N/A
- EPS Growth
- PLAY N/A
- NTLA N/A
- EPS
- PLAY 2.10
- NTLA N/A
- Revenue
- PLAY $2,197,200,000.00
- NTLA $43,086,000.00
- Revenue This Year
- PLAY $0.30
- NTLA $52.90
- Revenue Next Year
- PLAY $6.74
- NTLA N/A
- P/E Ratio
- PLAY $13.85
- NTLA N/A
- Revenue Growth
- PLAY 1.25
- NTLA N/A
- 52 Week Low
- PLAY $25.00
- NTLA $12.47
- 52 Week High
- PLAY $69.82
- NTLA $34.87
- Technical
- Relative Strength Index (RSI)
- PLAY 35.77
- NTLA 37.06
- Support Level
- PLAY $25.00
- NTLA $12.47
- Resistance Level
- PLAY $39.17
- NTLA $13.79
- Average True Range (ATR)
- PLAY 2.14
- NTLA 0.80
- MACD
- PLAY -0.92
- NTLA -0.06
- Stochastic Oscillator
- PLAY 22.61
- NTLA 12.10
About PLAY Dave & Buster's Entertainment Inc.
Dave & Buster's Entertainment Inc owns and operates nearly a hundred entertainment and dining establishments in the United States where customers can eat, drink, play games, and watch televised sports. Each store offers a full menu of entries and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. It derives maximum revenue from Entertainment.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.